Brokerages predict that Inogen Inc (NASDAQ:INGN) will report earnings of $0.27 per share for the current quarter, Zacks reports. Six analysts have made estimates for Inogen’s earnings. The lowest EPS estimate is $0.22 and the highest is $0.35. Inogen reported earnings per share of $0.31 during the same quarter last year, which suggests a negative year over year growth rate of 12.9%. The company is expected to issue its next earnings report on Tuesday, February 26th.

On average, analysts expect that Inogen will report full-year earnings of $2.10 per share for the current financial year, with EPS estimates ranging from $2.01 to $2.23. For the next fiscal year, analysts forecast that the firm will report earnings of $2.17 per share, with EPS estimates ranging from $2.13 to $2.22. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Inogen.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.21. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The business had revenue of $95.29 million for the quarter, compared to analyst estimates of $90.94 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. Inogen’s revenue was up 38.0% compared to the same quarter last year.

INGN has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $262.00 price target on the stock in a research note on Wednesday, August 22nd. Needham & Company LLC reiterated a “buy” rating and set a $280.00 price target (down previously from $296.00) on shares of Inogen in a research note on Wednesday, November 7th. BidaskClub downgraded shares of Inogen from a “sell” rating to a “strong sell” rating in a research note on Friday, November 16th. ValuEngine downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, November 7th. Finally, Piper Jaffray Companies lifted their price target on shares of Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $244.67.

In other news, insider Matt Scribner sold 2,000 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $281.23, for a total value of $562,460.00. Following the sale, the insider now owns 7,595 shares in the company, valued at approximately $2,135,941.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $282.57, for a total transaction of $2,966,985.00. Following the completion of the sale, the director now owns 8,797 shares in the company, valued at approximately $2,485,768.29. The disclosure for this sale can be found here. Insiders have sold 37,500 shares of company stock worth $9,008,475 in the last quarter. Corporate insiders own 5.29% of the company’s stock.

Several large investors have recently modified their holdings of INGN. Catalyst Capital Advisors LLC acquired a new stake in shares of Inogen in the 2nd quarter valued at $112,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Inogen in the 3rd quarter valued at $128,000. Advisory Services Network LLC boosted its stake in shares of Inogen by 162.5% in the 3rd quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 325 shares in the last quarter. First Quadrant L P CA acquired a new stake in shares of Inogen in the 3rd quarter valued at $134,000. Finally, Flagship Harbor Advisors LLC boosted its stake in shares of Inogen by 1,090.9% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 655 shares of the medical technology company’s stock valued at $157,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 96.94% of the company’s stock.

Shares of INGN stock opened at $142.96 on Friday. Inogen has a 1 year low of $112.78 and a 1 year high of $287.79. The firm has a market cap of $2.93 billion, a P/E ratio of 109.13, a P/E/G ratio of 2.67 and a beta of 1.56.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.